LSTA

#3589
Lisata Therapeutics, Inc. Common Stock
4.10
-6.82%
Сектор:
Базовая:
Валюта прибыли:
Дневной диапазон
4.10
4.10
Годовой диапазон
1.81
4.89
Дневное изменение
-6.82%
Месячное изменение
-11.26%
6-месячное изменение
+67.35%
Годовое изменение
+77.49%
Предыдущее закрытие
4.40
Open
4.10
Bid
Ask
Low
4.10
High
4.10
Объем
11
Open full chart

Financials

Overview Отчетность Statistics Dividends
Quarterly Annual
  • Market Capitalization 35.83 M
  • Employee 26
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.24
Price to sales ratio
24.82
Dividends per share
—
Dividend yield %
—

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Новости